Tumor markers in endocrine malignancies.
The development of assay techniques for the analysis of tumor markers in tissue extracts and in the peripheral circulation has had a major impact on the diagnosis and management of patients with endocrine neoplasms. In addition to eutopic and ectopic hormones, a variety of other tumor-derived products, including endocrine secretory proteins, enzymes, and oncodevelopmental antigens, can be assayed. The development of stimulatory tests to evaluate secretory reserve has been of particular value for the early detection of endocrine tumors and preneoplastic lesions in the multiple endocrine neoplasia syndromes. In addition, analysis of tumor markers has been of considerable importance for estimating total tumor burden and assessing responses to various therapeutic modalities. Recent advances in molecular biologic and cytogenetic technologies have the potential for prenatal detection of some forms of the inherited multiple endocrine neoplasia syndromes.
DeLellis
R A
RA
Tufts University School of Medicine, Boston, Massachusetts.
D006631:Amine Oxidase (Copper-Containing); D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen; D002864:Chromogranins; D004700:Endocrine System Diseases; D006728:Hormones; D006801:Humans; D009377:Multiple Endocrine Neoplasia; D009369:Neoplasms; D009384:Paraneoplastic Endocrine Syndromes; D010751:Phosphopyruvate Hydratase
D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen; D002864:Chromogranins; D006728:Hormones; D006631:Amine Oxidase (Copper-Containing); D010751:Phosphopyruvate Hydratase